James Danelle F, Kipps Thomas J
University of California, San Diego, Division of Hematology & Oncology, UCSD Moores Cancer Center, Room #4311, 3855 Health Sciences Drive, La Jolla, CA 92093-0820, USA.
Future Oncol. 2007 Feb;3(1):29-42. doi: 10.2217/14796694.3.1.29.
Alemtuzumab is a humanized monoclonal antibody specific for CD52, a glycosylphosphatidylinositol-anchored, lymphocyte-surface glycoprotein. Administration of alemtuzumab to patients with chronic lymphocytic leukemia depletes normal and neoplastic lymphocytes from the blood, spleen and marrow, but appears to be less effective in resolving lymphadenopathy. Owing to its activity in clearing leukemia cells of patients who are refractory to purine analogs, such as fludarabine, alemtuzumab became the first and only monoclonal antibody approved by the US FDA and other regulatory authorities for the treatment of chronic lymphocytic leukemia. Here we review the results of clinical studies evaluating the activity and safety of alemtuzumab when used alone or in combination with other antileukemia agents for the treatment of this disease.
阿仑单抗是一种特异性针对CD52的人源化单克隆抗体，CD52是一种糖基磷脂酰肌醇锚定的淋巴细胞表面糖蛋白。给慢性淋巴细胞白血病患者施用阿仑单抗可使血液、脾脏和骨髓中的正常淋巴细胞和肿瘤性淋巴细胞减少，但在消除淋巴结病方面似乎效果较差。由于其在清除对嘌呤类似物（如氟达拉滨）难治的患者白血病细胞方面的活性，阿仑单抗成为美国食品药品监督管理局（FDA）和其他监管机构批准用于治疗慢性淋巴细胞白血病的首个也是唯一的单克隆抗体。在此，我们综述了评估阿仑单抗单独使用或与其他抗白血病药物联合使用治疗该疾病时的活性和安全性的临床研究结果。
